Your trusted source for investing success

Tag: trials

Biomerica Announces Third Quarter Financial Results

Biomerica (Nasdaq:BMRA) today reported net sales of $4,433,785 for the nine months ending February 28, 2018, compared to $4,342,247 for the period ended February 28, 2017. Sales for the three months ending February 28, 2018 were $1,375,666 compared to $1,499,930 for the period ended February 28, 2017.

As quoted in the

Aptevo Therapeutics’ Bispecific Antibody APVO436 Shows Robust T-Cell Activation With Minimal Cytokine Release

Aptevo Therapeutics (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced the presentation of new data for APVO436, a bispecific antibody candidate targeting CD123 and CD3, at the American Association for Cancer Research (AACR) 2018 Annual Meeting. The preclinical data demonstrate potent T-cell cytotoxicity of tumors

BeiGene Initiates Global Phase 2 Trial of Anti-PD-1 Antibody Tislelizumab in Patients with Relapsed or Refractory Mature T-and NK-Cell Lymphomas

BeiGene (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, announced today that the first patient was dosed in a global Phase 2 clinical trial of tislelizumab, an investigational anti-PD-1 antibody, in patients with relapsed or refractory mature T-

Idera Pharmaceuticals Enters into a Clinical Development Support Agreement with Pillar Partners Foundation to Expand the Clinical Research on IMO-2125

Idera Pharmaceuticals (NASDAQ:IDRA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel oligonucleotide therapeutics for oncology and rare diseases, today announced it has entered into a clinical development support agreement with Pillar Partners Foundation.  Under the terms of the agreement Pillar Partners will provide direct funding

EyeGate Announces $11.25 Million Public Offering

EyeGate Pharmaceuticals (NASDAQ:EYEG) a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the eye, announced today the pricing of a public offering of an aggregate of 35,156,250 shares of common stock (or common stock equivalents) and warrants to purchase an aggregate of 35,156,250

Liver Biopsy Data from POISE Phase 3 Substudy Supports Obeticholic Acid’s Ability to Reverse or Stabilize Fibrosis and Cirrhosis in Primary Biliary Cholangitis (PBC) Patients

Intercept Pharmaceuticals (Nasdaq:ICPT) a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced clinical data from a liver biopsy-based substudy from the POISE Phase 3 trial suggesting that long-term OCA treatment in patients with PBC was associated with reversal or

Catalyst Biosciences Announces Korean Ministry of Food and Drug Safety Approves Addition of Sixth Cohort to the Phase 1/2 Trial of CB 2679d/ISU304

Catalyst Biosciences (Nasdaq:CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced that the Korean Ministry of Food and Drug Safety (MFDS) approved the addition of a sixth cohort to the Phase 1/2 trial of CB 2679d in individuals with severe hemophilia B following

Reata Provides Update on the Phase 2 Portion of the CARDINAL Study of Bardoxolone Methyl in Patients With Alport Syndrome

Reata Pharmaceuticals (Nasdaq:RETA) a clinical-stage biopharmaceutical company, today provided an update on the ongoing Phase 2 CARDINAL study of bardoxolone methyl (bardoxolone) in patients with chronic kidney disease (CKD) due to Alport syndrome.  The Phase 2 portion of CARDINAL enrolled 30 patients to receive bardoxolone orally, once-daily for two years. 

Are You Aware of the FDA's Plans for 2018?

Find out what's going on in our new report
 
Enter Your Log In Credentials
This setting should only be used on your home or work computer.

×

Privacy & Legal Policy

Privacy Policy

×
Investing News Network

Send this to a friend

Hi,
I thought you might find this interesting:
Medigus and HC Marbella International Hospital Announce Successful First Procedure in Spain

URL: https://investingnews.com/daily/life-science-investing/medical-device-investing/medigus-hc-marbella-international-hospital-announce-successful-first-procedure-spain/